SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (118)7/27/2001 10:03:11 AM
From: IRWIN JAMES FRANKEL   of 508
 
"Is it clear that ITMN would have the rights to a pegylated version of Infergen?"

I am pretty sure they do. It would be a foolish deal otherwise.

The longer half-life of Albuferon may be good but there will be limits - after all it is still alpha interferon. The limit should be the infusion numbers and I think that pegylation has aready closed most of the gap. In the clinic, the fewer and further between shots the better.

Perhaps, what ITMN should be doing is seeing if the albumin fusion approach could be used for Infergen, provided it would not be materially slower in getting to market over the pegylation approach.

We should not lose sight of the fact that Infergen is really a different drug than interferon alpha, while SGP, Roche and HGSI are all playing with alpha interferon.

ij
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News